Alkem Cold 5 mg/500 mg/5 mg Tablet
By Alkem Cold
Rx
10 Tablet in a Strip

Composition
Cetirizine(5mg) + Paracetamol(500mg) + Phenylephrine(5mg)

Manufacturer - Alkem Laboratories Ltd
Alkem Laboratories Limited, Devashish Building, Alkem House, Senapati Bapat Road, Lower Parel, Mumbai - 400 013.

Expires on or after
August, 2026

liver
Alkem Cold 5 mg/500 mg/5 mg Tablet is considered safe for individuals with liver disease based on the available data. There is no significant evidence indicating the need for dose adjustments specifically for patients with liver issues. However, it is always recommended to consult with your doctor before starting any medication, including Alkem Cold 5 mg/500 mg/5 mg Tablet, especially if you have liver concerns. Seeking professional medical advice ensures the safety and effectiveness of the treatment tailored to your specific health situation.

kidney
Alkem Cold 5 mg/500 mg/5 mg Tablet requires caution in patients with kidney disease. Dose adjustment may be necessary. Consult your doctor before use. Not recommended for severe kidney disease. End-stage kidney disease patients may experience increased drowsiness.

alcohol
It is not safe to drink alcohol while taking Alkem Cold 5 mg/500 mg/5 mg Tablet.

driving
Alkem Cold 5 mg/500 mg/5 mg Tablet typically does not impact driving ability.

pregnancy
Alkem Cold 5 mg/500 mg/5 mg Tablet may not be safe to use during pregnancy due to limited human studies and potential harmful effects on the developing baby as shown in animal studies. Consult your doctor for a thorough evaluation of benefits and risks before using.

breastfeeding
Alkem Cold 5 mg/500 mg/5 mg Tablet is likely safe to use while breastfeeding based on limited human data indicating minimal risk to the baby.
| Habit Forming | No |
| Chemical Class | - |
| Therapeutic Class | RESPIRATORY |
| Action Class | - |
₹28
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 11-Feb-2025
